Cube Biotech’s Post

From the basics of cell culture to advanced 3D models and therapeutic applications, the quality and consistency of media and reagents are key! High-quality components ensure reliable and reproducible results, vital for research and clinical progress. By using specialized growth factors, cytokines, and cutting-edge live-cell analysis technologies like the Incucyte® system, researchers can optimize cell culture conditions, enhance data accuracy, and drive innovative treatments forward. Our latest eBook highlights the importance of meticulous cell culture practices, showing how superior media and technologies can lead to groundbreaking advancements in research and therapy. 📚✨ Download now: https://ow.ly/LvUl50Tv7i2 #CellCulture #CellAnalyis #3DCellCulture #Organoids #Spheroids #Biotechnology

Read full news item👉 https://lnkd.in/e7VJWWJ2 Cygnus Technologies, LLC talks about the importance of understanding the complexity of Host Cell Protein (HCP) when developing your in-house analytical programs.

Over the past twenty years, the field of targeted protein degradation (TPD) has made significant strides as a novel therapeutic approach, utilizing either monovalent agents (molecular glues) or heterobifunctional molecules (PROTACs®). This collection of Best Practices outlines the fundamental principles and methodologies for developing PROTACs®. It includes three sections and a practical case study. 💻 Watch the webinars: https://buff.ly/4fPygsD 🔗 Download the set: https://buff.ly/4131kby

Dive into the world of membrane protein targets. How to utilize Grating Coupled Interferometry GCI for complex membrane proteins

If you want to learn more about PROTACs, check out this excellent work from the EFMC - European Federation for Medicinal Chemistry and Chemical Biology Best Practice team on PROTACs.

𝐘𝐨𝐮𝐫 𝐰𝐞𝐞𝐤𝐥𝐲 𝐂𝐑𝐈𝐒𝐏𝐑 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 𝐢𝐬 𝐡𝐞𝐫𝐞! With news from Precision BioSciences, Inc., Arbor Biotechnologies, research, reviews and more, we've got your covered! https://lnkd.in/eg_gYxv4 #crisprmedicinenews #crisprmedicine #crisprnews #geneediting #crispr #cmnweekly

Membrane proteins play vital roles in cellular functions, yet their study in native cellular settings poses significant challenges due to the complexity of the cell membrane. Cell-free systems offer a groundbreaking solution, enabling high-yield expression, purification, and reinsertion of MPs or their direct incorporation into membrane mimetic systems like liposomes for functional studies. 👉🏻 Discover our new blog post here about the current challenges and perspectives in proteoliposome research: https://lnkd.in/gjSRnDzT Join us in exploring the future of membrane protein research with cell-free systems and proteoliposomes! 🚀🔬 #MembraneProteins #Biotechnology #CellFreeSystems #Proteoliposomes #ResearchInnovation

Ready to take your oligonucleotide bioanalysis to the next level? ⏰ Only one day left to register for the live webinar and discover ground-breaking advancements that are redefining precision in oligonucleotide quantitation. Register now for an inside look into novel technologies and methodologies, enabling you to achieve unprecedented accuracy and efficiency in your bioanalytical workflows. Take advantage of the live Q&A session for a chance to get answers to your specific questions. Secure your spot: https://bit.ly/3NSg2un #Bioanalysis #oligonucleotide #bioanalysisandbeyond

"Bioanalysis Showdown!”👇🏼   Episode #9 of our Bioanalysis Showdown series is out! In their comparison of ligand-binding assays (LBA) and hybrid LC-MS/MS methods, Dawn Dufield, PhD, and Dominic Warrino, PhD, share examples where both approaches are needed and can be complementary, especially in the complex analysis of Antibody-Drug Conjugates (ADCs). #Bioanalysis #BioanalysisShowdown #LBA #HybridLCMS

Being a pioneer in your field is exciting, but it also comes with some unique challenges. When Alltrna started, there was no pre-existing framework for the production of chemically modified tRNAs. Over the years, the team has pioneered many of the processes and technologies to advance our first engineered tRNA medicines towards the clinic. In this insightful interview with David McCall of BioInsights, our Chief Technology Officer William Kiesman talks about what it is like leading such an innovative team and the processes it has developed, including product synthesis and scaling, proprietary analytical techniques to understand impurity profiles and inform downstream purification steps, and other drug design and quality control steps. He also discusses further advancements the field will need, including: 🔹the use of more ecologically sustainable, enzymatic processes to reduce waste 🔹the ligation of smaller oligonucleotides to make bigger, more complex systems 🔹innovations in oligonucleotide delivery to cells 📚Register for free to read the article in Nucleic Acid Insights: https://lnkd.in/grXYeGcn #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #StopCodonDisease #geneticmedicines #programmablemedicines